

Dominik Strzelecki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6491292/publications.pdf>

Version: 2024-02-01

52
papers

617
citations

687363

13
h-index

677142

22
g-index

61
all docs

61
docs citations

61
times ranked

1002
citing authors

#	ARTICLE	IF	CITATIONS
1	Disruption of Circadian Rhythm Genes in Obstructive Sleep Apnea Patients—Possible Mechanisms Involved and Clinical Implication. <i>International Journal of Molecular Sciences</i> , 2022, 23, 709.	4.1	21
2	“Leaky Gut” as a Keystone of the Connection between Depression and Obstructive Sleep Apnea Syndrome? A Rationale and Study Design. <i>Metabolites</i> , 2022, 12, 152.	2.9	2
3	Depression and Autoimmune Hypothyroidism—Their Relationship and the Effects of Treating Psychiatric and Thyroid Disorders on Changes in Clinical and Biochemical Parameters Including BDNF and Other Cytokines—A Systematic Review. <i>Pharmaceuticals</i> , 2022, 15, 391.	3.8	5
4	Serum levels of neuropeptide Y in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the double-blind randomized controlled PULSAR study). <i>Human Psychopharmacology</i> , 2021, 36, e2770.	1.5	1
5	The Relationship Between Antipsychotic Treatment and Plasma β -Endorphin Concentration in Patients with Schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 503-512.	2.2	3
6	Adiposity in Depression or Depression in Adiposity? The Role of Immune-Inflammatory-Microbial Overlap. <i>Life</i> , 2021, 11, 117.	2.4	8
7	The Influence of Probiotic Supplementation on Depressive Symptoms, Inflammation, and Oxidative Stress Parameters and Fecal Microbiota in Patients with Depression Depending on Metabolic Syndrome Comorbidity—PRO-DEMET Randomized Study Protocol. <i>Journal of Clinical Medicine</i> , 2021, 10, 1342.	2.4	5
8	Probiotics as a Treatment for “Metabolic Depression”? A Rationale for Future Studies. <i>Pharmaceuticals</i> , 2021, 14, 384.	3.8	11
9	Obstructive Sleep Apnea as an Acceleration Trigger of Cellular Senescence Processes through Telomere Shortening. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12536.	4.1	22
10	Comparison of thyroid-stimulating hormone levels in adolescents with schizophrenia, bipolar disorder, unipolar depression, conduct disorders, and hyperkinetic disorders. <i>Medicine (United States)</i> , 2021, 100, 1000000.	10	50
11	The association between serum levels of TNF- α and IL-6 in schizophrenic patients and their metabolic status—A case control study. <i>Journal of Neuroimmunology</i> , 2020, 347, 577344.	2.3	10
12	Can irisin become a biomarker of physical activity, or another metabolic risk assessment parameter, in psychiatric care patients?. <i>Postępy Psychiatrii i Neurologii</i> , 2020, 29, 205-214.	0.2	0
13	Plasma β -Endorphin Concentration and Antipsychotic Treatment Outcome in Schizophrenia: 1-Year Follow-Up. <i>Medical Science Monitor</i> , 2020, 26, e924307.	1.1	0
14	Plasma β -Endorphin Concentration and Antipsychotic Treatment Outcome in Schizophrenia: 1-Year Follow-Up. <i>Medical Science Monitor</i> , 2020, 26, e924307.	1.1	3
15	Does metabolic status affect serum levels of BDNF and MMP-9 in patients with schizophrenia?. <i>Nordic Journal of Psychiatry</i> , 2019, 73, 515-521.	1.3	9
16	A developmentally-stable pattern of premorbid schizoid-schizotypal features predicts psychotic transition from the clinical high-risk for psychosis state. <i>Comprehensive Psychiatry</i> , 2019, 90, 95-101.	3.1	8
17	Odor perception and hedonics in chronic schizophrenia and in first episode psychosis.	2.2	8
18	Short clinically-based prediction model to forecast transition to psychosis in individuals at clinical high risk state. <i>European Psychiatry</i> , 2019, 58, 72-79.	0.2	9

#	ARTICLE	IF	CITATIONS
19	<p>The Relationship Between Course of Illness and $\hat{1}^2$ -Endorphin Plasma Levels in Patients with Schizophrenia</p>. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 3609-3614.	2.2	5
20	Refeeding syndrome as treatment complication of anorexia nervosa. Psychiatria Polska, 2019, 53, 1113-1123.	0.5	9
21	â€œThird waveâ€•cognitive-behavioural therapy for eating disorders. Psychiatria I Psychologia Kliniczna, 2019, 19, 204-209.	0.2	0
22	Serum levels of interleukin 6 in schizophrenic patients during treatment augmentation with sarcosine (results of the <sc>PULSAR</sc> study). Human Psychopharmacology, 2018, 33, e2652.	1.5	11
23	A history of obstetric complications is associated with the risk of progression from an at risk mental state to psychosis. Schizophrenia Research, 2018, 197, 498-503.	2.0	4
24	Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study). Psychiatry Research, 2018, 268, 447-453.	3.3	15
25	In schizophrenia serum level of neurotrophin-3 (NT-3) is increased only if depressive symptoms are present. Neuroscience Letters, 2018, 684, 152-155.	2.1	11
26	Can microbiology affect psychiatry? A link between gut microbiota and psychiatric disorders. Psychiatria Polska, 2018, 52, 1023-1039.	0.5	18
27	Olfactory identification in patients with schizophrenia â€• the influence of $\hat{1}^2$ -endorphin and calcitonin gene-related peptide concentrations. European Psychiatry, 2017, 41, 16-20.	0.2	7
28	Deficits in the identification of pleasant odors predict the transition of an at-risk mental state to psychosis. Schizophrenia Research, 2017, 181, 49-54.	2.0	13
29	Evaluation of white matter structure changes, as assessed in tractography, and cognitive dysfunctions in patients with early onset schizophrenia and their first-degree relatives. Psychiatria Polska, 2017, 51, 735-750.	0.5	2
30	MMP-9 Serum Levels in Schizophrenic Patients during Treatment Augmentation with Sarcosine (Results of the PULSAR Study). International Journal of Molecular Sciences, 2016, 17, 1075.	4.1	10
31	Comparison of beta-endorphin and CGRP levels before and after treatment for severe schizophrenia. Neuropsychiatric Disease and Treatment, 2016, 12, 863.	2.2	11
32	Impact of lithium alone or in combination with haloperidol on selected oxidative stress parameters in human plasma<i>in vitro</i>. Redox Report, 2016, 21, 45-49.	4.5	3
33	BDNF serum levels in schizophrenic patients during treatment augmentation with sarcosine (results) Tj ETQq1 1 0.784314 rgBT /Overbor	3.3	12
34	Impact of lithium alone or in combination with haloperidol on oxidative stress parameters and cell viability in SH-SY5Y cell culture. Acta Neuropsychiatrica, 2016, 28, 38-44.	2.1	16
35	Glycine transporter inhibitor sarcosine changes neuronal and glial parameters in the left dorsolateral prefrontal cortex and glutamatergic parameters in the left hippocampus in stable schizophrenia. European Psychiatry, 2016, 33, s264-s264.	0.2	0
36	Comparison of Metabolite Concentrations in the Left Dorsolateral Prefrontal Cortex, the Left Frontal White Matter, and the Left Hippocampus in Patients in Stable Schizophrenia Treated with Antipsychotics with or without Antidepressants. $^1\text{H-NMR}$ Spectroscopy Study. International Journal of Molecular Sciences, 2015, 16, 24387-24402.	4.1	1

#	ARTICLE	IF	CITATIONS
37	Hypomania after augmenting venlafaxine and olanzapine with sarcosine in a patient with schizophrenia: a case study. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 533.	2.2	5
38	Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex. <i>International Journal of Molecular Sciences</i> , 2015, 16, 24475-24489.	4.1	24
39	Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia. <i>Nutrients</i> , 2015, 7, 8767-8782.	4.1	22
40	Levels of triglycerides, cholesterol, LDL, HDL and glucose in patients with schizophrenia, unipolar depression and bipolar disorder. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2015, 9, 168-176.	3.6	89
41	No changes of cardiometabolic and body composition parameters after 6-month add-on treatment with sarcosine in patients with schizophrenia. <i>Psychiatry Research</i> , 2015, 230, 200-204.	3.3	6
42	Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder. <i>Nordic Journal of Psychiatry</i> , 2015, 69, 346-353.	1.3	72
43	Supplementation of antipsychotic treatment with sarcosine " GlyT1 inhibitor " causes changes of glutamatergic 1NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia. <i>Neuroscience Letters</i> , 2015, 606, 7-12.	2.1	28
44	Two grams of sarcosine in schizophrenia – is it too much? A potential role of glutamate-serotonin interaction. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 263.	2.2	14
45	Analysis of Vitamin D Status in Major Depression. <i>Journal of Psychiatric Practice</i> , 2014, 20, 329-337.	0.7	31
46	A 10-Week Memantine Treatment in Bipolar Depression: A Case Report. Focus on Depressive Symptomatology, Cognitive Parameters and Quality of Life. <i>Psychiatry Investigation</i> , 2013, 10, 421.	1.6	22
47	P.3.c.023 Glycine plasma levels are not a useful predictor of recovery in patients treated with glycine and neuroleptics. <i>European Neuropsychopharmacology</i> , 2010, 20, S470-S471.	0.7	1
48	Pegylated interferon $\hat{\pm}$ and ribavirin therapy may induce working memory disturbances in chronic hepatitis C patients. <i>General Hospital Psychiatry</i> , 2008, 30, 501-508.	2.4	17
49	P.3.a.018 Changes in antisaccadic test, gain and negative symptoms in schizophrenic patients treated with glycine. <i>European Neuropsychopharmacology</i> , 2008, 18, S395-S396.	0.7	0
50	P.5.a.002 Peg-interferon alpha and ribavirin therapy may induce working memory disturbances in chronic hepatitis C patients. <i>European Neuropsychopharmacology</i> , 2007, 17, S526-S527.	0.7	1
51	Attention abnormalities in chronic hepatitis c (CHC) patients during peg-interferon alpha and ribavirin (peg-IFNalpha/RBV) therapy may persist after treatment discontinuation. <i>European Psychiatry</i> , 2007, 22, S303-S304.	0.2	0
52	peg-interferon alpha and ribavirin (peg-IFNalpha/RBV) therapy may induce working memory disturbances in chronic hepatitis c (CHC) patients. <i>European Psychiatry</i> , 2007, 22, S303.	0.2	0